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1. Introduction 
Hypogammaglobulinaemic patients are often started on immunoglobulin substitution 
therapy before antibody production is adequately evaluated. In such a situation, it is 
difficult to segregate transferred from antigen-induced specific antibody. Therefore we 
characterized changes in B-cell subpopulations in hypogammaglobulinaemic patients, 
including plasmablasts, in peripheral blood by flow cytometry after in vivo antigen 
challenge. We investigated the specificity of antibody production on the B-cell level by 
ELISPOT, which is independent of substitution therapy. 
Common variable immunodeficiency (CVID) is characterized by low serum levels of IgG, 
IgA, normal or low levels of IgM and impaired antibody responses after vaccination (Conley 
et al. 1999). The clinical presentation of CVID includes recurrent respiratory tract infections 
by encapsulated bacteria, autoimmunity, granuloma formations, enteropathy and increased 
risk of malignancies. The diagnosis is established by exclusion and elimination of other 
disorders affecting B-cell differentiation. Although standard treatment include long-term 
immunoglobulin replacement and antimicrobial therapy, the mortality rate of CVID patients 
is higher than that of the general population (Chapel et al. 2008; Cunningham-Rundles & 
Bodian 1999). 
Despite intensive research the immunopathogenesis of CVID has not yet been elucidated. It 
has been suggested that CVID is caused by defects in T cells, B cells, insufficient T-B cell 
interactions or impaired signaling required for B or T-cell maturation and function, but the 
characterization of the genetic defects remains unclear in the majority of patients. Molecular 
defects involving mutations in CD19 (van Zelm et al. 2006), ICOS (Grimbacher et al. 2003; 
Salzer et al. 2004), CD81 (van Zelm et al.), Msh5 (Sekine et al. 2007) and TACI (Castigli et al. 
2005; Mohammadi et al. 2009; Salzer et al. 2005) were found in less than 10% of CVID  
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patients (Cunningham-Rundles & Bodian 1999; Schaffer et al. 2007). CVID, therefore, is a 
heterogeneous group of patients expected to have multiple etiologies, all sharing similar 
immunologic and clinical characteristics. 
Although the precise pathogenesis of CVID remains unknown, a number of common 
abnormalities involving peripheral blood lymphocytes were described including differences 
in the number of naïve B cells (follicular B cells), CD21low B cells, transitional B cells, non-
class-switched IgM/IgD memory B cells (marginal zone-like B cells) (Klein et al. 1997; Shi et 
al. 2003; Tangye & Tarlinton 2009), class-switched memory B cells and plasmablasts (Carsetti 
et al. 2004; Sanchez-Ramon et al. 2008; Warnatz & Schlesier 2008; Weller et al. 2004). 
Specifically, CVID patients have reduced populations of CD27+ memory B cells (class-
switched memory B cells and marginal zone-like B cells) and increased percentages of 
undifferentiated B cells (immature CD21low B cells (Rakhmanov et al. 2009) and naïve CD27- 
B cells) associated with impaired class switching (Piqueras et al. 2003; Warnatz et al. 2002) 
and poor differentiation into plasma cells (Taubenheim et al. 2005) when compared to a 
control population (Ferry et al. 2005; Litzman et al. 2007). 
In addition, a vast array of T-cell abnormalities has been described in CVID 
patients, including defects in TCR-dependent T-cell activation (Thon et al. 1997), reduced 
frequency of antigen-specific T cells, impaired IL-2 release in CD4+ T cells (Funauchi et al. 
1995), decreased lymphocyte proliferation to mitogens and antigens (Chapel et al. 2008), 
lack of generation of antigen-primed T cells after prophylactic vaccination (Bryant et al. 
1990; Fischer et al. 1994; Giovannetti et al. 2007), impaired cytokine production (Fischer et al. 
1994; Thon et al. 1997), reduced expression of CD40L on activated T cells (Farrington et al. 
1994; Piqueras et al. 2003; Thon et al. 1997; Warnatz et al. 2002), significant decrease in Treg 
cells in CVID patients with granulomatous manifestations and immune cytopenias (Horn et 
al. 2009), significant reduction of frequency and absolute counts of CD4+ T cells, percentage 
increase in CD8+ T cells, decrease in distribution of CD4+ and CD8+ naïve T cells in 
comparison to healthy controls (Giovannetti et al. 2007; Mouillot et al. 2010). This complex 
list of T-cell abnormality likely plays a major role in determining the clinical course of CVID 
patients. 
In spite all of these multiple T-cell defects proposed as possible cause of CVID, the 
classification schemes presently in use are based on functional or phenotypic characteristics 
of B cells (assessment of immunoglobulin synthesis in vitro and phenotypic subsets of 
peripheral blood B cells): Bryant British classification (Bryant et al. 1990), Freiburg 
classification (Warnatz et al. 2002), Paris classification (Piqueras et al. 2003) and the recent 
EUROclass classification (Wehr et al. 2008). A few authors, however, suggested T-cell 
phenotyping as an aditional parameter for classifying CVID, and current efforts aim at the 
definition of combined T and B-cell phenotyping for the classification of CVID (Mouillot et 
al. 2010; Warnatz & Schlesier 2008). 
Although a lot is known about B cell subsets in of CVID patients, the way their B-cell 
subpopulations change in response to vaccination compared to normal individuals is largely 
unknown. Specifically, there are limited data as to antibody responses to protein or 
polysaccharide antigens and the quantity and quality of antibodies produced by patient 
from different groups of CVID patients. 
We focused on (1) specific in vitro antibody production by individual B cells following 
vaccinations by T-dependent (protein) and T-independent (polysaccharide) antigens and (2) 
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changes of B-cell subpopulation after vaccination in peripheral blood of CVID patients and 
healthy donors (Chovancova et al. 2011). 
2. Methodological approach 
2.1 Flow cytometry and assessment of plasmablasts 
Blood samples from examine subjects were collected between 7 and 12 a.m. to exclude 
diurnal variation of lymphocyte subsets. Lymphocytes and B-cell subpopulations were 
analyzed directly from peripheral blood or from isolated PBMC (Litzman et al. 2007). The 
main B cell subpopulations identified in PBMCs were CD21low B cells characterized as 
CD21lowCD38low, naïve B cells (IgD+CD27-), marginal zone-like B cells (IgD+CD27+), 
switched memory B cells (IgD-CD27+) and plasmablasts (IgD-CD27++CD38++). Cells were 
identified using monoclonal antibodies (mAbs): FITC-conjugated anti-CD38, PE-conjugated 
anti-IgD, PE-conjugated anti-CD21, PC5-conjugated anti-IgM (all from Pharmingen 
International, San Diego, CA, USA) and PC5-conjugated anti-CD27 (Beckman Coulter Miami, 
FL, USA). The B-cell subpopulations were analyzed by gating on CD19+ cells (PC7-
conjugated anti-CD19, Beckman Coulter, Marseille, France). Immunophenotyping of 
B lymphocytes was performed by five-colour cytometry Cytomix FC500 (Beckman Coulter 
Miami, FL, USA). The relative numbers of CD19+ B cells are showed as mean ± SD. 
2.2 Enzyme-linked immunosorbent spot assay (ELISPOT) 
The ELISPOT assay provides both qualitative (type of immune protein) and quantitative 
(number of responding cells) information (Czerkinsky et al. 1983). We have modified the 
ELISPOT technique for the detection of specific antibody responses to TET and PPS. 
96 wells microtitre plates (MultiScreenTM-HA, Millipore Corporation, Billerica, USA) were 
coated with tetanus toxoid (10 Lf/ml, ÚSOL, Prague, Czech Republic) and PPS (0.5 µg/ml, 
PNEUMO 23, Sanofi Pasteur, Lyon, France) antigens in carbonate buffer (pH = 9.6) overnight 
at 4 °C. Plates were washed 3 times with PBS containing 0.05% Tween 20 and subsequently 
incubated for 30 minutes at 37 °C with 100 µl per well of blocking buffer (1% solution of 
bovine serum albumin in PBS; Sigma Aldrich, Stenheim, Germany). Plates were then stored at 4 
°C until use. Peripheral blood mononuclear cells (PBMC), obtained from peripheral blood 
by gradient centrifugation (Lymphoprep, Axis-Shields PoC AS, Oslo, Norway) were added to 
the coated microtitre plates in RPMI 1640 medium (Sigma Aldrich) containing 10% heat-
inactivated FCS (LabMediaServis, Jaromer, Czech Republic) at 4 different dilutions (1.25 × 105; 
2.5 × 105; 5 × 105 and 1 × 106 in 100 µl/well for CVID patients and 0.625 × 105; 1.25 × 105; 
2.5 × 105; 5 × 105 cells in 100 µl/well for controls and cultured overnight at 37 °C in 5% CO2. 
After cells were washed off the plates 100 µl/well rabbit anti-human IgG, IgA or IgM 
conjugated to horseradish peroxidase (Dako Cytomation, Glostrup, Denmark; diluted 1:500 in 
PBS/Tween) were added to each well and incubated for 1h in the dark at room temperature. 
Plates were washed 3 times with PBS containing 0.05% Tween 20 followed by the addition 
of 100 µl/well of 3-amino-9-ethylcarbazole substrate solution (AEC, Sigma Aldrich) and 
incubated for 15 minutes at room temperature in the dark. Plates were rinsed with water 
and dried overnight at room temperature. 
The red-coloured spots were counted with the AID ELISPOT reader (AID, Autoimmun 
Diagnostika GmbH, Strassberg, Germany). This provided accurate recognition and calculation 
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of the spots and allowed objective differentiation between background and “real” spots. The 
results were expressed as a number of SFC per million B cells. 
2.3 Immunization of subjects 
Thirty-seven patients with established CVID (14 males, 23 females, age range 20 – 74 years) 
were examined. Twenty-six patients were treated with regular infusions of intravenous 
immunoglobulin (IVIG), six patients received regular subcutaneous immunoglobulin (SCIG) 
injections and one patient intramuscular immunoglobulin therapy (IMIG). Four patients 
were newly diagnosed and not yet on immunoglobulin replacement therapy at the time of 
the study. 
All CVID patients were vaccinated simultaneously with tetanus toxoid (TET) vaccine 
(ALTEANA, Sevapharma, Prague, Czech Republic) and unconjugated pneumococcal 
polysaccharide (PPS) antigens (PNEUMO 23, Sanofi Pasteur, Lyon, France), except patient no. 
34, who received PPS one year after TET. All patients on IVIG were vaccinated one week 
prior to administration of replacement therapy. 
The control group consisted of 80 healthy individuals. Fifty (16 males, 34 females, age range 
22 – 72 years) were vaccinated with TET; ten (4 males, 6 females, age range 15 – 46 years) 
were given PPS alone; twenty (8 males, 12 females, age range 14 – 50 years) received both 
TET and PPS. The study was approved by the Ethics Committee of Masaryk University, 
Brno and signed informed consent was obtained from each participant. 
2.4 Enzyme-linked immunosorbent assay (ELISA) and immunoglobulin quantification 
Commercially available kits were used for measuring specific IgG antibody levels against 
tetanus toxoid (VaccZymeTM Human Anti Tetanus Toxoid IgG EIA Kit, The Binding Site Group 
Ltd, Birmingham, United Kingdom) and IgG antibodies titers against IgA (Human Anti-IgA 
isotype IgG ELISA, BioVendor, Brno, Czech Republic) in serum. 
Trough serum levels of immunoglobulins IgG, IgA and IgM were measured in CVID 
patients prior to the IVIG infusion by nephelometry using the BN2 Nephelometer (Dade 
Behring, Marburg, Germany) according to the manufacturer’s instructions. 
2.5 Statistical analysis 
Data were analyzed using the STATISTICA software [StatSoft, Inc. (2007), STATISTICA (data 
analysis software system), version 8.0.; www.statsoft.com]. Mann-Whitney U-test and 
Wilcoxon matched pairs test were used for analyses of dependencies between particular 
parameters in studied groups; p < 0.05 was regarded as statistically significant. 
3. Laboratory findings 
3.1 Kinetics and optimal timing for detection of specific spot forming cells isolated 
from peripheral blood after vaccination 
The kinetics of anti-TET (T-dependent) specific antibody production by peripheral blood B 
cells was tested by ELISPOT assay in healthy volunteers from day 5 to day 9 after antigenic 
challenge. The same strategy was used in the assessment of anti-PPS (T-independent) 
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specific antibody production in healthy controls from day 1 to day 8 after antigen challenge. 
Day 7 was found to be optimal for the detection of specific antibody producing B-cells in 
peripheral blood for both antigens and all tested immunoglobulin isotypes (IgG, IgA, and 
IgM). Our findings are in agreement with previous studies (Kodo et al. 1984; Stevens et al. 
1979; Thiele et al. 1982). 
3.2 Kinetics and specific antibody responses against protein (T-dependent) and 
polysaccharide (T-independent) antigens in healthy individuals 
The group of healthy controls was vaccinated with protein antigen (tetanus toxoid, TET), 
unconjugated PPS antigens (PNEUMO 23) either separately or in combination. We found no 
significant difference in the number of SFC (IgG, IgA, IgM) against vaccinated antigens 
whether they were administered separately or simultaneously (Mann-Whitney U-test, p 
with range between 0.56 to 0.98). The number of specific SFC against both types of vaccines 
in the cohort of healthy controls is shown in Table 1. 
SFC/106 B cells 
 
MEDIAN MINIMUM MAXIMUM 
IgG anti-TET 10 371 964 86 747 
IgA anti-TET 532 24 9 707 
IgM anti-TET 0 0 0 
IgG anti-PPS 3 843 812 76 880 
IgA anti-PPS 33 935 3 200 186 384 
IgM anti-PPS 9 540 2 165 52 994 
Table 1. The number of spot forming cells against protein (n=70) and polysaccharide (n= 30) 
antigens in a group of healthy controls. SFC/106 B cells (spot forming cells per million 
CD19+ B cells); IgG, IgA, IgM anti-TET (IgG, IgA, IgM antibodies specific spot forming cells 
against tetanus toxoid); IgG, IgA, IgM anti-PPS (IgG, IgA, IgM antibodies specific spot 
forming cells against pneumococcal polysaccharides) 
3.3 Specific antibody response in subgroups of CVID patients 
CVID patients (n = 37) were classified according to the Freiburg (Warnatz et al. 2002) and 
EUROclass classification (Wehr et al. 2008) (Table 2),  allowing a comparative analysis of 
antibody production and clinical phenotype. As we had expected, the majority of our well-
defined CVID patients did not mount a specific humoral immune response against the two 
vaccines but several patients produced low numbers of vaccine-specific SFC (see below).  
As for EUROclass classification scheme, 3 patients of group smB+21norm (n = 7, patient no. 
18, 19, 20), 1 patient of group smB+21low (n = 6, patient no. 13) and 1 patient of group smB-
21low (n = 12, no. 1) had detectable IgG antibody responses against tetanus toxoid. In group 
smB+21low there was 1 patient (no. 14) who secreted IgM and another patient (no. 12) who 
formed IgA and IgM antibodies against PPS. The latter patient is the only one among the 
CVID group who formed specific antibodies of 2 different immunoglobulin isotypes. 
Regarding the group smB-21norm (n = 12), no specific antibody production was detected. In 
the Freiburg classification all patients with detectable antibody responses (no. 12, 13, 14, 18, 
19 and 20) were from group II the exception (no. 1) being a group Ia patient. 
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g/l titer SFC/106 B cells 
1 Ia smB-21low F 40 IMIG 2.78 <0.01 < 0.04 neg 344 0 0 0 0 0 
2 Ia smB-21low F 74 IVIG 5.39 <0.01 < 0.05 neg 0 0 0 0 0 0 
3 Ia smB-21low M 47 SCIG 3.92 0.06 0.19 neg 0 0 0 0 0 0 
4 Ia smB-21low M 50 IVIG 3.37 <0.01 < 0.05 neg 0 0 0 0 0 0 
5 Ia smB-21low M 36 IVIG 7.35 <0.01 0.05 neg 0 0 0 0 0 0 
6 Ib smB-21norm F 66 IVIG 5.82 <0.01 0.10 n. d. 0 0 0 0 0 0 
7 Ib smB-21norm F 34 no 2.01 <0.01 < 0.05 neg 0 0 0 0 0 0 
8 Ib smB-21norm M 30 IVIG 5.77 <0.01 < 0.05 neg 0 0 0 0 0 0 
9 Ib smB-21norm F 20 no 0.66 <0.01 0.13 1:50 0 0 0 0 0 0 
10 Ib smB-21norm F 44 IVIG 3.16 <0.01 0.10 neg 0 0 0 0 0 0 
11 Ib smB-21norm M 55 IVIG 5.09 <0.01 0.32 neg 0 0 0 0 0 0 
12 II smB+21low F 71 IVIG 6.29 0.08 0.29 neg 0 0 0 0 2562 659 
13 II smB+21low M 19 IVIG 4.49 <0.01 0.07 neg 407 0 0 0 0 0 
14 II smB+21low M 24 no 4.99 <0.01 0.20 neg 0 0 0 0 0 104 
15 II smB+21low F 54 IVIG 6.95 <0.01 0.15 1:100 0 0 0 0 0 0 
16 II smB+21low F 41 SCIG 6.14 <0.01 0.05 neg 0 0 0 0 0 0 
17 II smB+21low M 57 SCIG 5.66 0.02 < 0.05 neg 0 0 0 0 0 0 
18 II smB+21norm F 19 SCIG 6.75 0.05 0.75 neg 185 0 0 0 0 0 
19 II smB+21norm M 44 IVIG 5.91 0.22 < 0.05 neg 713 0 0 0 0 0 
20 II smB+21norm M 44 IVIG 6.37 <0.01 0.10 neg 231 0 0 0 0 0 
21 II smB+21norm M 31 IVIG 3.80 0.02 0.07 n. d. 0 0 0 0 0 0 
22 II smB+21norm F 68 IVIG 6.35 <0.01 < 0.05 neg 0 0 0 0 0 0 
23 II smB+21norm M 59 IVIG 6.86 0.04 0.06 neg 0 0 0 0 0 0 
24 II smB+21norm F 41 IVIG 5.26 <0.01 0.08 neg 0 0 0 0 0 0 
Table 2. Continues on next page 
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g/l titer SFC/106 B cells 
25 II smB-21low F 42 IVIG 8.15 <0.01 0.50 neg 0 0 0 0 0 0 
26 II smB-21low F 58 IVIG 5.98 <0.01 < 0.05 neg 0 0 0 0 0 0 
27 II smB-21low F 57 IVIG 8.15 <0.01 < 0.05 neg 0 0 0 0 0 0 
28 II smB-21low M 34 IVIG 6.21 <0.01 0.05 neg 0 0 0 0 0 0 
29 II smB-21low F 43 IVIG 6.27 <0.01 < 0.05 neg 0 0 0 0 0 0 
30 II smB-21low F 50 SCIG 4.48 <0.01 < 0.05 neg 0 0 0 0 0 0 
31 II smB-21low F 28 IVIG 5.62 <0.01 < 0.05 neg 0 0 0 0 0 0 
32 II smB-21norm F 44 IVIG 6.75 <0.01 0.05 neg 0 0 0 0 0 0 
33 II smB-21norm F 61 IVIG 7.54 0.09 < 0.05 neg 0 0 0 0 0 0 
34 II smB-21norm F 27 no 2.35 <0.01 0.45 neg 0 0 0 0 0 0 
35 II smB-21norm F 40 IVIG 7.10 <0.01 0.09 neg 0 0 0 0 0 0 
36 II smB-21norm F 40 SCIG 8.51 <0.01 < 0.05 neg 0 0 0 0 0 0 
37 II smB-21norm M 19 IVIG 7.00 <0.01 < 0.05 neg 0 0 0 0 0 0 
Table 2. (continued) Results of the ELISPOT assay in group of CVID patients. F (female);  
M (male); n.d. (not done); SFC/106 B cells (spot forming cells per million CD19+ B cells); IgG, 
IgA, IgM anti-TET (IgG, IgA, IgM specific spot forming cells against tetanus toxoid); IgG, 
IgA, IgM anti-PPS (IgG, IgA, IgM specific spot forming cells against pneumococcal 
polysaccharides); IgG anti-IgA (IgG antibodies against IgA) 
The decreased production of SFC in CVID patients was independent of replacement 
immunoglobulin treatment: four CVID patients without substitution therapy showed the 
same defect in the production of SFC and specific antibodies after vaccination as CVID 
patients on replacement therapy. 
3.4 Changes of B-cell subpopulations in peripheral blood one week after vaccination 
The mean percentage of CD19+ B cells was 11 ± 4 % in healthy controls and 13 ± 7.6 % in 
CVID patients before vaccination. One week after vaccination the percentages were 
unchanged (12 ± 5 % in healthy controls and 13 ± 6.7 % in CVID patients). 
We then examined the changes of absolute and relative numbers of plasmablasts and other 
B lymphocyte subpopulations in the peripheral blood one week after antigen challenge (Fig. 
1, 2). In healthy controls no statistically significant changes in absolute and relative numbers 
of switched memory B cells were found between the two measurement time points, before  
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Fig. 1. Changes of relative numbers of B-cell subpopulations in healthy controls (HC; n = 19; 
a) and CVID patients (CVID; n = 29; b) before (0) and one week (7) after antigen challenge. 
21low (CD21low B cells), N (naïve B cells), MZ (marginal zone - like B cells), PB27++ and 
PB38++ (plasmablasts), SM (class-switched memory B cells) 
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and one week after vaccination. However, a highly significant increase in absolute as well as 
relative numbers of plasmablasts gated as IgD-CD27++ (PB CD27++) cells and IgM-CD38++ 
(PB CD38++) cells (p<0.001 in both cases) occurred (Fig. 3), while the absolute and relative 
numbers of CD21low B cells (p<0.02), naïve B cells (p<0.001) and MZ-like B cells (p<0.001) 
decreased. In contrast, among the cohort of CVID patients no statistically significant changes 
of examined cellular subpopulations, including plasmablasts (Fig. 1, 2 and 3) were observed 
except for a slight increase in smB cells to a level still well below the levels of healthy 
controls. This increase was statistically significant in Wilcoxon matched pairs test. 
The fact that the number of plasmablasts corresponds with the number of SFC strongly 
suggest that the examination of peripheral blood plasmablasts on day 7 after vaccination can 
be used as a surrogate marker for specific antibody responses in normal controls and as a 
diagnostic procedure to identified CVID and other patients with defect in terminal B-cell 
differentiation (Chovancova et al. 2011). 
4. Consequences 
4.1 Hypogammaglobulinaemic patients and diagnostic vaccination 
Poor vaccination responses to protein and polysaccharide antigens is essential for definition-
based diagnosis of CVID (Conley et al. 1999). Quantitative assessment of specific antibody in 
serum is routinely performed by ELISA assay. However CVID patients are often started on 
immunoglobulin substitution therapy before antibody production is adequately evaluated. 
In such a situation, it is difficult to segregate transferred from antigen-induced specific 
antibody. We have designed a in vitro functional measurement of antibody production on 
the B-cell level using the ELISPOT technique, which is independent of substitution therapy 
(Chovancova et al. 2011). In addition, we monitored changes in B-cell subpopulations, 
including plasmablasts, in peripheral blood by flow cytometry after in vivo antigenic 
challenge. 
The defect in the antibody production and SFC reduction observed in a cohort of CVID 
patients are not secondary to Ig substitution since the same defects were also seen in four 
CVID patients before starting Ig replacement therapy. IVIG treated CVID patients were 
vaccinated exactly one week before administration of immunoglobulin substitution. In this 
manner the theoretically possible influence of immunoglobulin replacement therapy on the 
generation of SFC was reduced. 
Prior to this study, specific antibody production in substituted CVID patients following 
vaccination had been evaluated in serum. Goldacker et al. (Goldacker et al. 2007) measured 
specific antibodies in serum by ELISA assay. The contribution of parallel immunoglobulin 
substitution on antibody titers was difficult to correct and required a relatively complicated 
vaccination formula. Based on these calculations the authors reported a decrease in serum 
antibody levels against T-dependent and T-independent antigens in CVID patients between 
IVIG infusions. Using a meningococcal polysaccharide vaccine, Rezaei et al. described 
decreased vaccination response against meningococcal polysaccharide measured in serum 
of CVID patients while on IVIG (Rezaei et al. 2008; Rezaei et al. 2010). Immunization with 
a protein neoantigen, e.g. bacteriophage, and investigation of immune response with 
neutralization assay brought similar results (Ochs et al. 1971). Nevertheless, there is very little 
quantitative data correlating individual vaccination responses to proposed functional    
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Fig. 2. Changes of absolute numbers of B-cell subpopulations in healthy controls (HC;  
n = 19; a) and CVID patients (CVID; n = 29; b) before (0) and one week (7) after antigen 
challenge. 21low (CD21low B cells), N (naïve B cells), MZ (marginal zone - like B cells), PB27++ 
and PB38++ (plasmablasts), SM (class-switched memory B cells) 
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Fig. 3. Development of plasmablasts after vaccination. Plasmablasts (red arrows) were gated 
from CD19+ B cells (gate in column 1) as IgD-CD27++ (column 2) and IgM-CD38++ (column 3). 
The cells were investigated before (day 0) and on day 7 after vaccination. HC – healthy 
control; CVID – CVID patient, PB27++ and PB38++ – plasmablasts 
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classifications of CVID (Goldacker et al. 2007; Rezaei et al. 2008). Our group of CVID patients 
was arranged according to the Freiburg (Warnatz et al. 2002) and EUROclass classification 
(Wehr et al. 2008). As expected, the majority of our well-defined CVID patients (30/37) failed 
to mount a specific humoral immune response when analysed by SFCs collected from 
peripheral blood before and after immunization. The seven CVID patients who responded had 
much smaller quantities of specific SFC compared to healthy donors. All but one patient with 
measurable antibody responses belong to group II of the Freiburg classification or EUROclass 
group smB+ which represent those CVID patients with nearly normal numbers of class-
switched memory B cells. Patients in these groups are characterized by milder complications 
of the disease compared to other groups (Alachkar et al. 2006; Wehr et al. 2008). 
4.2 Novel diagnostic tool using flow cytometry in hypogammaglobulinaemic patients 
with vaccination 
During the last few years a number of studies described differences between B-cell 
subpopulations of CVID patients and those of healthy volunteers but the kinetics of these 
changes after encounter with an antigen in vivo (Pinna et al. 2009) has not previously been 
explored. We investigated the dynamic changes of CD21low B cells, naïve B cells, marginal 
zone-like B cells, plasmablasts and switched memory B cells of CVID patients compared to 
healthy donors (Chovancova et al. 2011). Previous studies showed that memory B cells and 
plasmablasts have different kinetics in peripheral blood (Stevens et al. 1979). Plasmablasts 
reach their peak on day 7 after encounter with the antigen in peripheral blood while 
switched memory B cells showed a marked increase in number on day 14 after antigen 
challenge (Pinna et al. 2009). The absolute number of naïve B lymphocytes is determined by 
the generation of new naïve B cells from the bone marrow pool (a slow process) and by 
acute loss of naïve B lymphocytes via further maturation after antigen encounter (Agenes et 
al. 2000). Statistically significant up-regulation of naïve B cells and its continued 
accumulation after antigen challenge in CVID patients indicates disturbed conversion of 
undifferentiated B cells to more mature B-cell stages in germinal centers. Differentiation is 
crucially dependent on T-lymphocyte help, suggesting that the basic defects in the majority 
of CVID patients are not in B cells but in helper T-lymphocytes (Borte et al. 2009; Fischer et 
al. 1994; Fischer et al. 1996; Thon et al. 1997). 
The reduced numbers of switched memory B cells which correlate with clinical 
complications (Ko et al. 2005; Viallard et al. 2006) and failure to increase the number of 
plasmablasts after antigen challenge may be explained by insufficient signals from helper T 
cells of CVID patients. In previous studies we and others have shown that B cells of CVID 
patients are able to produce antibodies if they are exposed in vitro to helper T-lymphocyte 
from healthy donors or to appropriate cytokines (Borte et al. 2009; Fischer et al. 1994; Fischer 
et al. 1996; Thon et al. 1997), 55. Taubenheim et al. studied B-cell differentiation in lymph 
nodes from three CVID patients with splenomegaly and found distinct blocks in terminal 
plasma cell development but normal expression of a key regulator of terminal plasma cell 
differentiation, Blimp-1 (Taubenheim et al. 2005).  Moreover, the clinically important 
observation that B cells from CVID patients may produce antibodies under certain 
circumstances correlates with the fact that CVID patients lacking IgA are able to generate 
IgG anti-IgA antibodies in vivo (Horn et al. 2007). Among our cohort of vaccinated CVID 
patients, two patients from subgroups Ib and II (Table 2) produced IgG anti-IgA antibodies 
in low titers although these two patients did not respond to vaccination. 
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Our observation that the majority of CVID patients lack antigen specific spot forming B cells 
and fail to increase circulating plasmablasts following in vivo antigen challenge provides 
a rapid screening test to demonstrate defective antibody responses in CVID patients, even 
when on replacement IVIG therapy (Chovancova et al. 2011). 
5. Conclusion and clinical implications 
Identification of circulating plasmablasts after vaccination is a new simple flow based test to 
assess antibody responses in hypogammaglobulinaemic patients, even if on immunoglobulin 
(IVIG or SCIG) replacement therapy. 
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